


International Digestive Endoscopy Network 2020

September 25(Fri) – 26(Sat), 2020 BEXCO, Busan, Korea

Name	Tae Il KIM	
Country	Korea	
Organization	Yonsei University College of Medicine	
Current Position	Professor	

Educational Background

1985 - 1991: Medical Degree, Yonsei University College of Medicine

1993 - 1995: Master course of Medical science,
Graduate School, Yonsei University, Seoul, Korea

1995 – 2002: Ph. D. course of Medical science,
Graduate School, Yonsei University, Seoul, Korea

Professional Experiences

2002.3. – 2007.2.: Assistant Professor of Internal Medicine,
Division of Gastroenterology, Yonsei University College of Medicine

2006.8. – 2008.7.: Research fellow, Post-doc, Division of Gastroenterology,
Vanderbilt University Medical Center, TN, USA

2007.3. – 2012.2.: Associate Professor of Internal Medicine,
Division of Gastroenterology, Yonsei University College of Medicine

2012.3.- Present: Professor of Internal Medicine,
Division of Gastroenterology, Yonsei University College of Medicine

2014.5.- Present: Director of Yonsei Cancer Prevention Center, Yonsei Cancer Center, Severance Hospital

Professional Organizations

Member of Korean Society of Gastroenterology, Korean Society of Gastrointestinal Endoscopy, Korean Association for the Study of Intestinal Disease, American Gastroenterology Association, American Association of Cancer Research.

2017.4.-2019.4.: Secretary General of Korean Association for the Study of Intestinal Disease

2018.12.- 2019.12: President of Korean Society of Cancer Prevention

2019.11.- present: Director of Scientific Committee of Korean Society of Gastroenterology

Main Scientific Publications

1. Next-generation sequencing with comprehensive bioinformatics analysis facilitates somatic mosaic APC gene mutation detection in patients with familial adenomatous polyposis. Kim B, Won D, Jang M, et al. BMC Medical Genomics 2019;12(1): 103.
2. Outcomes of stent insertion and mortality in obstructive stage IV colorectal cancer patients through 10 year duration. Park YE, Park Y, Park SJ, et al. Surgical Endoscopy 2019;33(4): 1225-1234.
3. Association of Family History with Cancer Recurrence, Survival, and the Incidence of Colorectal Adenoma in Patients with Colorectal Cancer. Park Y, Park SJ, Cheon JH, et al. Journal of cancer prevention 2019;24(1): 1-10.
4. Screening for Lung Cancer Using Low-dose Chest Computed Tomography in Korean Long-term Colorectal Cancer Survivors. Park JS, Kang B, Park Y, et al. Journal of cancer prevention 2019;24(1): 48-53.
5. Resting heart rate is an independent predictor of advanced colorectal adenoma recurrence. Park J, Kim JH, Park Y, et al. PLOS ONE 2018;13:e0193753.
6. Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism. Kim JH, Lee KJ, Seo Y, et al. Sci Rep 2018;8:409.
7. Postoperative adjuvant chemotherapy is associated with a lower incidence of colorectal adenomas in patients with previous colorectal cancer. Lee HS, Kim SB, Lee HJ, et al. Gastrointest Endosc 2018;87:688-94.e2.

International Digestive Endoscopy Network 2020

September 25(Fri) – 26(Sat), 2020 BEXCO, Busan, Korea

8. Physical Inactivity and Unhealthy Metabolic Status Are Associated with Decreased Natural Killer Cell Activity. Jung, YS, et al. *Yonsei Med J* 2018;59(4):554-562.
 9. Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients. Park JW, Lee JH, Park YH, et al. *World Journal of Gastroenterology* 2017;23:5196-205.
 10. The effects of physical activity and body fat mass on colorectal polyp recurrence in patients with previous colorectal cancer. Park J, Kim JH, Lee HJ, et al. *Cancer Prevention Research* 2017;10:478-84.
 11. The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma. Han MS, Lee HJ, Park SJ, et al. *Int J of Colorectal Dis*, 2017;32:1223-6.
 12. Comparison of Colonoscopy Surveillance Outcomes Between Young and Older Colorectal Cancer Patients. Kim SB, Lee HJ, Park SJ, et al. *Journal of cancer prevention* 2017;22(3): 159-165.
 13. Development of a Robotic Colonoscopic Manipulation System, Using Haptic Feedback Algorithm. Woo J, Choi JH, Seo JT, et al. *Yonsei Med J* 2017;58:139-43.
 14. Tumor characteristics associated with malignant large bowel obstruction in stage IV colorectal cancer patients undergoing chemotherapy. Kim DH, Kim B, Choi JH, et al. *International Journal of Colorectal Disease* 2016;31:1767-74.
 15. Long-Term Effects of Bone Marrow-Derived Mesenchymal Stem Cells in Dextran Sulfate Sodium-Induced Murine Chronic Colitis. Lee HJ, Oh SH, Jang HW, et al. *Gut Liver* 2016;10:412-9.
 16. High-risk metachronous polyps are more frequent in patients with traditional serrated adenomas than in patients with conventional adenomas: a multicenter prospective study. Yoon JY, Kim HT, Hong SP, et al. *Gastrointestinal Endoscopy* 2015;82:1087-93.
 17. The effect of pre-diagnostic aspirin use on the prognosis of stage III colorectal cancer. Kim B, Park SJ, Hong SP, et al. *International Journal of Clinical and Experimental Medicine* 2015;8:13435-45.
 18. Risk Factors for Recurrent High-Risk Polyps after the Removal of High-Risk Polyps at Initial Colonoscopy. Jang HW, Park SJ, Hong SP, et al. *Yonsei Med J* 2015;56:1559-65.
 19. The Role of Barrier Dysfunction and Change of Claudin Expression in Inflammatory Bowel Disease. Kim TI. *Gut and Liver* 2015;9:699-700.
 20. Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1, and activating PPAR γ in colorectal cancer. Moon CM, Kwon J-H, Kim JS, Oh S-H, et al. *International Journal of Cancer* 2014;134:519-529.
 21. Differential expression of CD133 based on microsatellite instability status in human colorectal cancer. Park JJ, Kwon J-h, Oh S-H, et al. *Molecular Carcinogenesis* 2014;53:E1-E10.
 22. Type II Diabetes, Metformin Use, and Colorectal Neoplasia: Mechanisms of Action and Implications for Future Research. Lee JH, Kim TI. *Current Colorectal Cancer Reports* 2014;10:105-13.
 23. Chemopreventive drugs: Mechanisms via inhibition of cancer stem cells in colorectal cancer. Kim TI. *World J Gastroenterol* 2014;20:3835-46.
 24. Colorectal stenting: An advanced approach to malignant colorectal obstruction. Hong SP, Kim TI. *World J Gastroenterol* 2014;20:16020-8.
 25. Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. Lee JH, Jeon SM, Hong SP, et al. *Digestive and Liver Disease* 2012;44:1042-7.
 26. Myofibroblast keratinocyte growth factor reduces tight junctional integrity and increases claudin-2 levels in polarized Caco-2 cells. Kim TI, Poulin EJ, Blask E, et al. *Growth Factors* 2012;30:320-32.
 27. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Lee JH, Kim TI, Jeon SM, et al. *Int J Cancer*. 2012;131:752-9.
-